Involvement of phosphorylation in doxorubicin-mediated myofibril degeneration: An immunofluorescence microscopy analysis

Circulation Research

Volumn 80, Issue 1, 1997, Pages 52-61

  Sussman, Mark A ^a,c   Hamm Alvarez, Sarah F ^b   Vilalta, Patricia M ^b   Welch, Sara ^a   Kedes, Larry ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c CINCINNATI CHILDREN S HOSPITAL RESEARCH FOUNDATION   (United States)

Author keywords

cardiomyocyte; doxorubicin; myofibril; phosphorylation

Indexed keywords

1 (5 ISOQUINOLINESULFONYL) 2 METHYLPIPERAZINE; DOXORUBICIN; ISOQUINOLINE DERIVATIVE; N (2 GUANIDINOETHYL) 5 ISOQUINOLINESULFONAMIDE; N (2 METHYLAMINOETHYL) 5 ISOQUINOLINESULFONAMIDE; OKADAIC ACID; PHORBOL 13 ACETATE 12 MYRISTATE; PHOSPHOPROTEIN PHOSPHATASE INHIBITOR; PHOSPHOTRANSFERASE; TRITON X 100;

ANIMAL CELL; ARTICLE; CARDIOMYOPATHY; CARDIOTOXICITY; CELL DEGENERATION; CONTROLLED STUDY; HEART MUSCLE CELL; IMMUNOFLUORESCENCE MICROSCOPY; NEWBORN; NONHUMAN; PHOSPHORYLATION; PRIORITY JOURNAL; RAT; SARCOMERE; SIGNAL TRANSDUCTION; THIN FILAMENT;

EID: 0031015354     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.80.1.52     Document Type: Article

References (56)

1. Mann DL, Urabe Y, Kent RL, Vinciguerra S, Cooper G IV. Cellular versus myocardial basis for the contractile dysfunction of hypertrophied myocardium. Circ Res. 1991;68:402-415.
2. Schaper J, Froede TA, Hein S, Buck A, Hashizume H. Speiser B, Freidl A, Bleese N. Impairment of the myocardium ultrastructure and changes of the cytoskeleton in dilated cardiomyopathy. Circulation. 1991;83:504-514.
3. Steinhertz LJ, Steinhertz PG, Tan C, Cardiac failure and dysrhythmias 6-19 years after anthracycline therapy: a series of 15 patients. Med Pediatr Oncol. 1995;24:352-361.
4. Freter CE, Lee TC, Billingham ME, Chak L, Bristow MR. Doxorublcin cardiac toxicity manifesting seven years after treatment. Am J Med. 1986;80:483-485.
5. Hull BE, Lockwood TD. Toxic cardiomyopathy: the effect of antipsychotic-antidepressant drugs and calcium on myocardial protein degradation and structural integrity. Toxicol Appl Pharmacol. 1986; 86:308-324.
6. Sharp WW, Terracio L, Borg TK, Samarel AM. Contractile activity modulates actin synthesis and turnover in cultured neonatal rat heart cells. Circ Res. 1993;73:172-183.
7. Komuro I, Katoh Y, Kaida T, Shibazaki Y, Kurabayashi M, Hoh E, Takaku F, Yazaki Y. Mechanical loading stimulates cell hypertrophy and specific gene expression in cultured rat cardiac myocytes, J Biol Chem. 1991;266:1265-1268.
8. Ito H, Miller SC, Billingham ME, Akimoto H, Torti SV, Wade R, Gahlmann R, Lyons G, Kedes L, Torti FM. Doxorubicin selectively inhibits muscle gene expression in cardiac muscle cells in vivo and in vitro. Proc Nat Acad Sci U S A. 1990;87:4275-4279.
9. Olson RD, Mushlin PS. Doxorubicin cardiotoxicity: analysis of prevailing hypotheses, FASEB J. 1990;4:3076-3086.
10. Dunn J. Doxorubicin-induced cardiomyopathy, J Pediatr Oncol Nurs. 1994;11:152-160.
11. Kurabayashi M, Jeyaseelan R, Kedes L. Amineoplastic agent doxorubicin inhibits myogenic differentiation of C2 myoblasts. J Biol Chem. 1993;268:5524-5529.
12. Kurabayashi M, Dutta S, Kedes L, Serum-inducible factors binding to an activating transcription factor motif regulate transcription of the Id2A promoter during myogenic differentiation. J Biol Chem. 1994; 269:31162-31170.
13. Kurabayashi M, Dutta S, Jeyaseelan R, Kedes L. Doxorubicin-induced Id2A gene transcription is targeted at an ATF/CRE motif through novel mechanisms involving protein kinases distinct from protein kinase C and protein kinase A. Mol Cell Biol 1995;15: 6386-6397.
14. Harauchi T, Hirata M. Effects of p-phenylenediamines and adriamycin on primary culture of rat skeletal muscle cells. Toxicol Lett. 1993;66:35-46.
15. Pollard TD, Cooper JA. Actin and actin binding proteins: a critical evaluation of mechanisms and functions. Annu Rev Biochem. 1986; 55:987-1035.
16. Xis D, Peng B, Sesok DA, Peng I. Probing actin incorporation into myofibrils using Asp11 and His73 actin mutants. Cell Motil Cytoskel. 1993;26:115-124.
17. Hein S, Scheffold T, Schaper J. Ischemia induces early changes to cytoskeletal and contractile proteins in diseased human myocardium. J Thorac Cardiovasc Surg. 1995;110:89-98.
18. Takahashi K, Hattori A. α-Actinin is a component of the Z-filament, a structural backbone of skeletal muscle Z-disks. J Biochem. 1989; 105:529-536.
19. 1-adrenoceptor-mediated hypertrophy of rat cardiomyocytes. J Clin Invest. 1987;80:1194-1199.
20. Hidaka H, Inagaki M, Kawamoto S, Sasaki Y. Isoqiunolinesulfonamides, novel and potent inhibitors of cyclic nucleotide dependent protein kinase and protein kinase C. Biochemistry. 1984;23: 5036-5048.
21. Sussman MA, Sakhi S, Barrientos P, Ito M, Kedes L. Tropomodulin in rat cardiac muscle: localization of protein is independent of messenger RNA distribution during myofibrillar development. Circ Res. 1994;75:221-232.
22. Przyklenk K, Sussman MA, Simkhovitch BZ, Kloner RA. Does ischemic preconditioning trigger translocation of protein kinase C in the canine model? Circulation. 1995;92:1546-1557.
23. Schnapp BJ. Viewing single microtubules by video-light microscopy. Methods Enzymol. 1986;134:561-573.
24. Disatnik M-H, Buraggi G, Mochly-Rosen D. Localization of protein kinase C isozymes in cardiac myocytes. Exp Cell Res, 1994;210:287-297.
25. Hamm-Alvarez SF, Kim PY, Sheetz MP. Regulation of microtubule- dependent vesicle transport in CV-1 cells and extracts. J Cell Sci. 1993;106:955-966
26. Braconi A, Church DJ, Vallotton MB, Lang U. Functional inhibition of protein kinase C-mediated effects in myocardial tissue is due to the phosphatase 2A. Biochem J. 1992;286:851-855.
27. Bogoyevitch MA, Parker PJ, Sugden PH. Characterization of protein kinase C isotype expression in adult rat heart: protein kinase C-ε is a major isotype present, and it is activated by phorbol esters, epinephrine, and endothelin. Circ Res. 1993;72:757-767.
28. Yuan S, Sunhara FA, Sen AK Tumor-promoting phorbol esters inhibit cardiac functions and induce redistribution of protein kinase C in perfused beating rat heart. Circ Res. 1987;61:372-378.
29. Lin Z, Eshelman J, Grund C, Fischman DA, Masaki T, Franke WW, Holtzer H. Differential response of myofibrillar and cytoskeletal proteins in cells treated with phorbol myristate acetate. J Cell Biol. 1989;108:1079-1091.
30. ++ content in developing myotubes. Dev Biol. 1982; 89:460-474
31. Lui JD, Wood JG, Raynor RL, Wang Y-C, Noland TA, Ansari AA, Kuo JF. Subcellular distribution and immunocytochemical localization of protein kinase C in myocardium, and phosphorylation of troponin in isolated myocytes stimulated by isoproterenol or phorbol ester, Biochem Biophys Res Commun. 1989;162;1105-1110.
32. Neumann J, Boknik P, Herzig S, Schmitz W, Scholz H, Gupta RC, Watanabe AM. Evidence for physiological functions of protein phosphatases in the heart: evaluation with okadaic acid, Am J Physiol. 1993;265:H257-H266.
33. Eriksson JE, Brautigan DL, Valee R, Olmstead J, Fujiki H, Goldman RD. Cytoskeletal integrity in interphase cells requires protein phosphatase activity. Proc Nat Acad Sci U S A, 1992;89:11093-11097.
34. Strohm GH, Payne CM, Alberts DS, Peng T-M, Moon TE, Bahl JJ, Bressler R. Cardiotoxic effects of doxorubicin with and without carnitine. Arch Pathol Lab Med. 1982;106:181-185.
35. Puceat M, Hilal-Dandan R, Strulovici B, Brunton LL, Brown JH, Differential regulation of protein kinase C isoforrns in isolated neo natal and adult rat cardiomyocytes. J Biol Chem. 1994;269: 16938-16944.
36. Rybin VO, Steinberg SF. Protein kinase C isoform expression and regulation in the developing rat heart. Circ Res. 1994;74:299-309.
37. Clerk A, Bogoyevitch MA, Parker PJ, Sugden PH. Down-regulation of protein kinase C isotypes during postnatal development of rat heart. Biochem Soc Trans. 1993;21:385S. Abstract.
38. Kohout TA, Rogers TB. Use of a PCR-based method to characterize protein kinase C isoform expression in cardiac cells. Am J Physiol. 1993;264:C1350-C1359.
39. Clerk A, Bogoyevitch MA, Anderson MB, Sugden PH. Differential activation of protein kinase C isoforms by endothelin-1 and phenylephrine and subsequent stimulation of p42 and p44 mitogen-activated protein kinases in ventricular myocytes cultured from neonatal rat hearts. J Biol Chem. 1994;269:32848-32857.
40. Disatnik MH, Jones SN, Mochly-Rosen D. Stimulus-dependent subcellular localization of activated protein kinase C: a study with acidic fibroblast growth factor and transforming growth factor-beta 1 in cardiac myocytes. J Mol Cell Cardiol. 1995;27:2473-2481.
41. Johnson JA, Adak S, Mochly-Rosen, D. Prolonged phorbol ester treatment down-regulates protein kinase C isozymes and increases contraction rate in neonatal cardiac myocytes. Life Sci. 1995; 57:1027-1038.
42. Johnson JA, Mochly-Rosen D. Inhibition of the spontaneous rate of contraction of neonatal cardiac myocytes by protein kinase C isozymes: A putative role for the ε isozyme. Circ Res. 1995;76:654-663.
43. Prekeris R, Mayhew MW, Cooper JB, Terrian DM. Identification and actin localization of an actin-binding motif that is unique to the epsilon isoform of protein kinase C and participates in the regulation of synaptic function. J Cell Biol. 1996;132:77-90.
44. Gautel M, Zuffardi O, Freiburg A, Labeit S. Phosphorylation switches specific for the cardiac isoform of myosin binding protein C: a modulator of cardiac contraction? EMBO J. 1995; 14:1952-1960.
45. Venema RC, Raynor RL, Noland TA Jr, Kuo JF. Role of protein kinase C in the phosphorylation of cardiac myosin light chain kinase 2. Biochem J. 1993;294:401-406.
46. Venerna RC, Kuo JF. Protein kinnse C-mediated phosphorylation of troponin I and C-protein in isolated myocardial cells is associated with inhibition of myofibrillar actomyosin MgATPase. J Biol Chem. 1993;268:2705-2711.
47. 2+-dependent actomyosin MgATPase activity and troponin T binding to tropomyosin-F-actin complex, Biochem J. 1992;288:123-129.
48. Yamazaki T, Komuro I, Kudoh S, Zou Y, Shiojima I, Mizuno T, Takano H, Hiroi Y, Ueki K, Tobe K. Mechanical stress activates protein kinase cascade of phosphorylation in neonatal rat cardiac myocytes. J Clin Invest. 1995;96:438-446.
49. Jakab G, Kiss E, Kranias EG, Edes I. Effect of thyroid status on basal phosphorylation of cardiac myofibrillar phosphoproteins in rats, Cardioscience, 1994;5:19-24.
50. Tritton TR, Hickman JA. How to kill cancer cells: membranes and cell signaling as targets in cancer chemotherapy. Cancer Cells. 1990;2:95-105.
51. DalleDone I, Milzani A, Contini P, Bernardini G, Colombo R. Interaction of cardiac α-actinin and actin in the presence of doxorubicin. Exp Mol Pathol. 1992;56:229-238.
52. Lewis W, Beckenstein K, Shapiro L, Puszkin S. Doxorobicin and covalently crosslinked doxorubicin derivatives binding to purified cardiac thinfilament proteins in vitro. Exp Mol Palhol. 1985;43:64-73.
53. 2+ transients observed in cardiac myocytes isolated from guinea-pig heart, Can J Physiol Pharmacol. 1994;72:622-631.
54. + accumulation in cardiac sarcoplasmic reticulum. Eur J Pharmacol. 1994; 268:365-373.
55. Lanzi C, Gambetta RA, Perego P, Banfi P, Franzi A, Guazzoni L, Zunino F. Protein kinase C activation by anthracyclines in Swiss 3T3 cells. Int J Cancer. 1992;47:136-142.
56. Banfi P, Parolini O, Lanzi C, Gambetta RA. Lipid peroxidation, phosphoinositide turnover and protein kinase C activation in human platelets treated with anthracyclines and their complexes with Fe(III). Biochem Pharmacol. 1992;43:1521-1527.